Surrogate Endpoints Acceptable in AML Trials, Says FDA

In the case of drugs used for newly diagnosed acute myeloid leukemia (AML), surrogate endpoints have been validated, says the US Food and Drug Administration.
Medscape Medical News

source https://www.medscape.com/viewarticle/967529?src=rss